FoxO6 cKO, similar to the effects of Ang‐II, significantly attenuated cardiac hypertrophy after TAC surgery, as evidenced by the ventricular wall thickness measured by ultrasound and the cross‐sectional area of CMs (Figure S12C–I). This evidence concerns the gene FOXO6 and persistent truncus arteriosus.